Frank Verholen

Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial

Maha Hussain, Bertrand Tombal, Fred Saad et al. · Journal of Clinical Oncology · 2023 · 215 citations · Full text

Medicine, Oncology, Pharmacology +17

Evaluation of Clinically Relevant Drug–Drug Interactions and Population Pharmacokinetics of Darolutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Results of Pre-Specified and Post Hoc Analyses of the Phase III ARAMIS Trial

Neal D. Shore, Christian Zurth, Robert E. Fricke et al. · Targeted Oncology · 2019 · 94 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Deep and Durable Prostate-specific Antigen Response to Darolutamide with Androgen Deprivation Therapy and Docetaxel, and Association with Clinical Outcomes for Patients with High- or Low-volume Metastatic Hormone-sensitive Prostate Cancer: Analyses of the Randomized Phase 3 ARASENS Study

Fred Saad, Maha Hussain, Bertrand Tombal et al. · European Urology · 2024 · 52 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Resistant pure red cell aplasia after allogeneic stem cell transplantation with major ABO mismatch treated by escalating dose donor leukocyte infusion

Frank Verholen, M Stalder, Claudine Helg et al. · European Journal Of Haematology · 2004 · 48 citations · Full text

Medicine, Hematology, Immunology +17

Safety and Survival Outcomes of¹⁷⁷Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer with Prior²²³Ra treatment: The RALU Study

Kambiz Rahbar, Markus Essler, Kim M. Pabst et al. · Journal of Nuclear Medicine · 2022 · 37 citations · Full text

Medicine, Oncology, Radiation Oncology +17